Celldex Therapeutics Share Holder Equity 2010-2022 | CLDX

Celldex Therapeutics share holder equity from 2010 to 2022. Share holder equity can be defined as the sum of preferred and common equity items
Celldex Therapeutics Annual Share Holder Equity
(Millions of US $)
2021 $419
2020 $209
2019 $94
2018 $124
2017 $236
2016 $265
2015 $290
2014 $212
2013 $320
2012 $96
2011 $69
2010 $75
2009 $74
Celldex Therapeutics Quarterly Share Holder Equity
(Millions of US $)
2022-03-31 $398
2021-12-31 $419
2021-09-30 $437
2021-06-30 $182
2021-03-31 $194
2020-12-31 $209
2020-09-30 $230
2020-06-30 $238
2020-03-31 $84
2019-12-31 $94
2019-09-30 $101
2019-06-30 $110
2019-03-31 $113
2018-12-31 $124
2018-09-30 $128
2018-06-30 $128
2018-03-31 $134
2017-12-31 $236
2017-09-30 $219
2017-06-30 $231
2017-03-31 $248
2016-12-31 $265
2016-09-30 $217
2016-06-30 $235
2016-03-31 $260
2015-12-31 $290
2015-09-30 $319
2015-06-30 $346
2015-03-31 $376
2014-12-31 $212
2014-09-30 $239
2014-06-30 $265
2014-03-31 $292
2013-12-31 $320
2013-09-30 $157
2013-06-30 $177
2013-03-31 $195
2012-12-31 $96
2012-09-30 $91
2012-06-30 $95
2012-03-31 $108
2011-12-31 $69
2011-09-30 $81
2011-06-30 $92
2011-03-31 $66
2010-12-31 $75
2010-09-30 $52
2010-06-30 $60
2010-03-31 $68
2009-12-31 $74
2009-09-30 $-2
2009-06-30 $4
2009-03-31 $12
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.061B $0.005B
CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00